SC
SLNO

Stephens Consulting’s Soleno Therapeutics SLNO Stock Holding History

Stephens Consulting’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$252 – 1039
2025
Q2 		$252 Sell
3
-7
-70% -$524 ﹤0.01% 1024
2025
Q1 		$715 Buy
+10
New +$487 ﹤0.01% 810

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stephens Consulting's SLNO Position: Q3 2025 in Review

Stephens Consulting sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 3 shares — an estimated $252 sold.

Stephens Consulting first reported a position in SLNO in Q1 2025 and held it in 2 quarters. The position peaked at $715 in Q1 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Stephens Consulting reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 3 Soleno Therapeutics shares in Q3 2025, an estimated $252.
  • Stephens Consulting first reported a position in Soleno Therapeutics in Q1 2025 and held it in 2 quarters.
  • Stephens Consulting's Soleno Therapeutics position peaked at $715 in Q1 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.